Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
Biomarkers
Lung cancer screening
Mortality
Myocardial infarction
Risk assessment
Troponin
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
28
06
2023
accepted:
22
03
2024
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
epublish
Résumé
Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ("LUSI" study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4% had low, 12.8% intermediate and 4.8% elevated cTnI, respectively. Over a median follow up of 11.87 years a total of 439 deaths occurred, including 67 caused by cardiac events. Within the first 5 years after cTnI measurement, intermediate or elevated cTnI levels showed approximately 1.7 (HR = 1.69 [95% CI 0.57-5.02) and 4.7-fold (HR = 4.66 [1.73-12.50]) increases in risk of cardiac death relative to individuals with unquantifiable/low cTnI, independently of age, sex, smoking and other risk factors. Within this time interval, a risk model based on age, sex, BMI, smoking history and cTnI showed a combined area under the ROC curve (AUC) of 73.6 (58.1-87.3), as compared to 70.4 (53.3-83.5) for a model without cTnI. Over the time interval of > 5-10 years after blood donation, the relative risk associations with cTnI and were weaker. cTnI showed no association with mortality from any other (non-cardiac) cause. Our findings show that cTnI may be of use for identifying individuals at elevated risk specifically of short-term cardiac mortality in the context of LC screening.
Identifiants
pubmed: 38531926
doi: 10.1038/s41598-024-57889-z
pii: 10.1038/s41598-024-57889-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7197Informations de copyright
© 2024. The Author(s).
Références
Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409. https://doi.org/10.1056/NEJMoa1102873 (2011).
doi: 10.1056/NEJMoa1102873
pubmed: 21714641
de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513. https://doi.org/10.1056/NEJMoa1911793 (2020).
doi: 10.1056/NEJMoa1911793
pubmed: 31995683
Paci, E. et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 72, 825–831. https://doi.org/10.1136/thoraxjnl-2016-209825 (2017).
doi: 10.1136/thoraxjnl-2016-209825
pubmed: 28377492
Pastorino, U. et al. Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening. Eur. J. Cancer (Oxford, England : 1990) 118, 142–148. https://doi.org/10.1016/j.ejca.2019.06.009 (2019).
Becker, N. et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int. J. Cancer. 146, 1503–1513. https://doi.org/10.1002/ijc.32486 (2020).
Krist, A. H. et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA, J. Am. Med. Assoc. 325, 962–970. https://doi.org/10.1001/jama.2021.1117 (2021).
doi: 10.1001/jama.2021.1117
Kauczor, H. U. et al. ESR/ERS statement paper on lung cancer screening. Eur. Radiol. 30, 3277–3294. https://doi.org/10.1007/s00330-020-06727-7 (2020).
doi: 10.1007/s00330-020-06727-7
pubmed: 32052170
Ten Haaf, K., van der Aalst, C. M., de Koning, H. J., Kaaks, R. & Tammemägi, M. C. Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges. Int. J. Cancer. 149, 250–263. https://doi.org/10.1002/ijc.33578 (2021).
Ruparel, M. et al. Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax 74, 1140–1146. https://doi.org/10.1136/thoraxjnl-2018-212812 (2019).
doi: 10.1136/thoraxjnl-2018-212812
pubmed: 31558626
Balata, H. et al. Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. Lung Cancer (Amsterdam, Netherlands) 124, 148–153. https://doi.org/10.1016/j.lungcan.2018.08.006 (2018).
doi: 10.1016/j.lungcan.2018.08.006
pubmed: 30268454
Howard, D. H., Richards, T. B., Bach, P. B., Kegler, M. C. & Berg, C. J. Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. Cancer 121, 4341–4347. https://doi.org/10.1002/cncr.29677 (2015).
doi: 10.1002/cncr.29677
pubmed: 26372542
González Maldonado, S. et al. Overdiagnosis in lung cancer screening: Estimates from the German lung cancer screening intervention trial. Int. J. Cancer 148, 1097–1105. https://doi.org/10.1002/ijc.33295 (2021).
Apple, F. S. & Collinson, P. O. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin. Chem. 58, 54–61. https://doi.org/10.1373/clinchem.2011.165795 (2012).
doi: 10.1373/clinchem.2011.165795
pubmed: 21965555
Shah, A. S. et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: A cohort study. Lancet 386, 2481–2488. https://doi.org/10.1016/s0140-6736(15)00391-8 (2015).
doi: 10.1016/s0140-6736(15)00391-8
pubmed: 26454362
pmcid: 4765710
Bossard, M. et al. Factors independently associated with cardiac troponin I levels in young and healthy adults from the general population. Clin. Res. Cardiol. 106, 96–104. https://doi.org/10.1007/s00392-016-1026-5 (2017).
doi: 10.1007/s00392-016-1026-5
pubmed: 27535138
Willeit, P. et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J. Am. Coll. Cardiol. 70, 558–568. https://doi.org/10.1016/j.jacc.2017.05.062 (2017).
doi: 10.1016/j.jacc.2017.05.062
pubmed: 28750699
pmcid: 5527070
Welsh, P. et al. Cardiac troponin T and troponin I in the general population. Circulation 139, 2754–2764. https://doi.org/10.1161/circulationaha.118.038529 (2019).
doi: 10.1161/circulationaha.118.038529
pubmed: 31014085
pmcid: 6571179
Farmakis, D., Mueller, C. & Apple, F. S. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur. Heart J. 41, 4050–4056. https://doi.org/10.1093/eurheartj/ehaa083 (2020).
doi: 10.1093/eurheartj/ehaa083
pubmed: 32077940
Blankenberg, S. et al. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium. Eur. Heart J. 37, 2428–2437. https://doi.org/10.1093/eurheartj/ehw172 (2016).
doi: 10.1093/eurheartj/ehw172
pubmed: 27174290
pmcid: 4982535
Zethelius, B., Johnston, N. & Venge, P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: A community-based cohort study. Circulation 113, 1071–1078. https://doi.org/10.1161/circulationaha.105.570762 (2006).
doi: 10.1161/circulationaha.105.570762
pubmed: 16490824
Lan, N. S. R. et al. High-sensitivity cardiac troponin i improves cardiovascular risk prediction in older men: HIMS (the health in men study). J. Am. Heart Assoc. 8, e011818. https://doi.org/10.1161/jaha.118.011818 (2019).
doi: 10.1161/jaha.118.011818
pubmed: 30819029
pmcid: 6474925
Kaaks, R. et al. Lung function impairment in the German Lung Cancer Screening Intervention Study (LUSI): Prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality. Transl. Lung Cancer Res. 11, 1896–1911. https://doi.org/10.21037/tlcr-22-63 (2022).
doi: 10.21037/tlcr-22-63
pubmed: 36248328
pmcid: 9554689
Becker, N. et al. Randomized study on early detection of lung cancer with MSCT in Germany: Results of the first 3 years of follow-up after randomization. J. Thorac. Oncol. 10, 890–896. https://doi.org/10.1097/jto.0000000000000530 (2015).
doi: 10.1097/jto.0000000000000530
pubmed: 25783198
Becker, N. et al. Randomized study on early detection of lung cancer with MSCT in Germany: Study design and results of the first screening round. J. Cancer Res. Clin. Oncol. 138, 1475–1486. https://doi.org/10.1007/s00432-012-1228-9 (2012).
doi: 10.1007/s00432-012-1228-9
pubmed: 22526165
Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3–95-year age range: The global lung function 2012 equations. Eur. Respir. J. 40, 1324–1343. https://doi.org/10.1183/09031936.00080312 (2012).
doi: 10.1183/09031936.00080312
pubmed: 22743675
pmcid: 3786581
262021 Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org/2021-gold-reports/ (2021).
Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ 340, c332. https://doi.org/10.1136/bmj.c332 (2010).
doi: 10.1136/bmj.c332
pubmed: 20332509
pmcid: 2844940
Mascalchi, M. et al. Pulmonary emphysema and coronary artery calcifications at baseline LDCT and long-term mortality in smokers and former smokers of the ITALUNG screening trial. Eur. Radiol. 33, 3115–3123. https://doi.org/10.1007/s00330-023-09504-4 (2023).
doi: 10.1007/s00330-023-09504-4
pubmed: 36854875
pmcid: 10121526
Balbi, M. et al. Automated coronary artery calcium and quantitative emphysema in lung cancer screening: Association with mortality, lung cancer incidence, and airflow obstruction. J. Thorac. Imaging https://doi.org/10.1097/rti.0000000000000698 (2023).
doi: 10.1097/rti.0000000000000698
pubmed: 36656144
pmcid: 10287055
Nilsson, U. et al. Ischemic ECG abnormalities are associated with an increased risk for death among subjects with COPD, also among those without known heart disease. Int. J. Chronic Obstr. Pulm. Dis. 12, 2507–2514. https://doi.org/10.2147/copd.S136404 (2017).
doi: 10.2147/copd.S136404
Wan, E. S. et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA 326, 2287–2298. https://doi.org/10.1001/jama.2021.20939 (2021).
doi: 10.1001/jama.2021.20939
pubmed: 34905031
pmcid: 8672237
Waschki, B. et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur. Respir. J. 55, 1. https://doi.org/10.1183/13993003.01314-2019 (2020).
Adamson, P. D. et al. Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 72, 1126–1137. https://doi.org/10.1016/j.jacc.2018.06.051 (2018).
doi: 10.1016/j.jacc.2018.06.051
pubmed: 30165984
pmcid: 6119211
Nilsson, U. et al. Cardiac biomarkers of prognostic importance in chronic obstructive pulmonary disease. Respir. Res. 21, 162. https://doi.org/10.1186/s12931-020-01430-z (2020).
doi: 10.1186/s12931-020-01430-z
pubmed: 32590988
pmcid: 7318493
Neukamm, A. et al. The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm. Med. 16, 164. https://doi.org/10.1186/s12890-016-0319-9 (2016).
doi: 10.1186/s12890-016-0319-9
pubmed: 27887619
pmcid: 5124304
Clerico, A., Lippi, G. J. J. o. L. & Medicine, P. The state-of-the-art of “high-sensitivity” immunoassay for measuring cardiac troponin I and T. J. Lab. Precis. Med. 3, 53 (2018).
Bogle, B. M., Ning, H., Goldberger, J. J., Mehrotra, S. & Lloyd-Jones, D. M. A simple community-based risk-prediction score for sudden cardiac death. Am. J. Med. 131, 532-539.e535. https://doi.org/10.1016/j.amjmed.2017.12.002 (2018).
doi: 10.1016/j.amjmed.2017.12.002
pubmed: 29273191
Deo, R. et al. Development and validation of a sudden cardiac death prediction model for the general population. Circulation 134, 806–816. https://doi.org/10.1161/circulationaha.116.023042 (2016).
doi: 10.1161/circulationaha.116.023042
pubmed: 27542394
pmcid: 5021600